Clinical Trial Update: Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients [Phase 4]

View source ↗

Summary

Phase 4 trial updates Befotertinib as adjuvant therapy for stage IA2-IB non-small cell lung cancer; the study is currently recruiting and examining 3-year disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib

Snippet

Sponsor: Fudan University | Conditions: 3-year Disease-free Survival | Phase 4 | Status: RECRUITING